Recent Posts
- Amolyt Pharma Announces Positive Safety and Efficacy Results from Second Patient Cohort in its Phase 2a Trial of AZP-3601 for the Treatment of Hypoparathyroidism
- Ciliatech presents groundbreaking concept in glaucoma implants, first to bypass opening anterior eye chamber
- Amolyt Pharma Announces Positive Efficacy and Safety Data from First Cohort of Phase 2a Study of AZP-3601 in Patients with Hypoparathyroidism at the American Society for Bone and Mineral Research 2022 Annual Meeting
- Amolyt Pharma Announces Two Presentations, Including Phase 2a Data for AZP-3601 in Patients with Hypoparathyroidism, at the American Society for Bone and Mineral Research 2022 Annual Meeting
- US EPA about to approve Amoéba’s biocide for use in closed cooling systems
Archives
- October 2022
- September 2022
- August 2022
- June 2022
- May 2022
- April 2022
- March 2022
- February 2022
- October 2021
- September 2021
- August 2021
- July 2021
- May 2021
- April 2021
- March 2021
- January 2021
- December 2020
- November 2020
- October 2020
- September 2020
- July 2020
- April 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- July 2019
- March 2019
- February 2019
- December 2018
- November 2018
- December 2017
- September 2017
- April 2017